BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17137401)

  • 1. Targeted anti-cancer therapies for renal cancer.
    Amato RJ; Jac J
    Drugs; 2006; 66(17):2161-71. PubMed ID: 17137401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens.
    Amato RJ
    Ann Oncol; 2005 Jan; 16(1):7-15. PubMed ID: 15598929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in targeted therapy for renal cell carcinoma.
    Clark PE
    Curr Opin Urol; 2007 Sep; 17(5):331-6. PubMed ID: 17762626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New targets and drugs for treatment of advanced renal cell carcinoma].
    Rohde D
    Aktuelle Urol; 2005 Apr; 36(2):125-30. PubMed ID: 15902572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI
    Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecularly targeted therapies for renal cell cancer: TRAIL research advances.
    Buttyan R; Mian BM
    J Urol; 2007 May; 177(5):1606. PubMed ID: 17437767
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted agents for the treatment of advanced renal cell carcinoma.
    Stadler WM
    Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives.
    Minguet J; Smith KH; Bramlage CP; Bramlage P
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):219-33. PubMed ID: 25963382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for renal cell cancer: current perspectives.
    van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
    Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
    Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-clear cell advanced kidney cancer: is there a gold standard?
    Sánchez P; Calvo E; Durán I
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced renal cell carcinoma: current and emerging management strategies.
    Escudier B
    Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.
    Furge KA; MacKeigan JP; Teh BT
    Lancet Oncol; 2010 Jun; 11(6):571-8. PubMed ID: 20381423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.
    Agarwala SS; Case S
    Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.